Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($7.42) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.01 million for the quarter.
Jupiter Neurosciences Trading Down 13.8%
JUNS traded down $0.23 during trading on Tuesday, hitting $1.47. The stock had a trading volume of 2,964 shares, compared to its average volume of 315,477. The firm has a market cap of $1.33 million, a PE ratio of -0.08 and a beta of 1.87. Jupiter Neurosciences has a 12 month low of $1.55 and a 12 month high of $101.25. The company has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $17.61.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on JUNS shares. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Jupiter Neurosciences has an average rating of “Sell”.
Get Our Latest Research Report on Jupiter Neurosciences
Institutional Investors Weigh In On Jupiter Neurosciences
An institutional investor recently raised its stake in Jupiter Neurosciences stock. Vestor Capital LLC increased its holdings in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Free Report) by 144,607.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 970,985 shares of the company’s stock after purchasing an additional 970,314 shares during the period. Vestor Capital LLC owned approximately 2.68% of Jupiter Neurosciences worth $365,000 at the end of the most recent reporting period.
About Jupiter Neurosciences
Jupiter Neurosciences is a clinical-stage biotechnology company developing treatments for neurodegenerative and other central nervous system disorders, as well as certain rare diseases. Its research centers on neuroinflammation and the potential therapeutic effects of resveratrol. The company’s lead product candidate, JOTROL, is a proprietary oral formulation of resveratrol designed to improve its absorption. JOTROL is investigational and is being studied for potential use in conditions including mucopolysaccharidosis type I and Friedreich’s ataxia; it is not an approved treatment.
Featured Stories
- Five stocks we like better than Jupiter Neurosciences
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
